335 related articles for article (PubMed ID: 29883838)
1. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Schrock AB; Zhu VW; Hsieh WS; Madison R; Creelan B; Silberberg J; Costin D; Bharne A; Bonta I; Bosemani T; Nikolinakos P; Ross JS; Miller VA; Ali SM; Klempner SJ; Ou SI
J Thorac Oncol; 2018 Sep; 13(9):1312-1323. PubMed ID: 29883838
[TBL] [Abstract][Full Text] [Related]
2. Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
Xu H; Shen J; Xiang J; Li H; Li B; Zhang T; Zhang L; Mao X; Jian H; Shu Y
Cancer Manag Res; 2019; 11():6343-6351. PubMed ID: 31372039
[No Abstract] [Full Text] [Related]
3. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
[TBL] [Abstract][Full Text] [Related]
4. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
Enrico D; Lacroix L; Chen J; Rouleau E; Scoazec JY; Loriot Y; Tselikas L; Jovelet C; Planchard D; Gazzah A; Mezquita L; Ngo-Camus M; Michiels S; Massard C; Recondo G; Facchinetti F; Remon J; Soria JC; André F; Vassal G; Friboulet L; Besse B
JTO Clin Res Rep; 2020 Jun; 1(2):100023. PubMed ID: 34589930
[TBL] [Abstract][Full Text] [Related]
6. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
8. [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].
Shao Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):381-387. PubMed ID: 32429639
[TBL] [Abstract][Full Text] [Related]
9. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
10. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
11. Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
Tao Z; Liu J; Li T; Xu H; Chen K; Zhang J; Zhou H; Sun J; Han J; Guo Z; Yang H; Cao WM; Hu X
Front Oncol; 2021; 11():741142. PubMed ID: 34650924
[TBL] [Abstract][Full Text] [Related]
12. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
13. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
14. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno T; Nakaoku T; Tsuta K; Tsuchihara K; Matsumoto S; Yoh K; Goto K
Transl Lung Cancer Res; 2015 Apr; 4(2):156-64. PubMed ID: 25870798
[TBL] [Abstract][Full Text] [Related]
15. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
16.
Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
[TBL] [Abstract][Full Text] [Related]
17. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
18. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
19. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
20. Diverse
Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]